MedTrace Logo

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

NCT00401401 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-12-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer

Conditions

Interventions

DRUG

zalutumumab

Eight weekly infusions

DRUG

cisplatin

Infusions

PROCEDURE

Radiotherapy

Daily in the treatment period

Sponsors & Collaborators

  • Genmab

    lead INDUSTRY

Principal Investigators

  • Vincent Gregoire, MD professor · St-Luc University Hospital, Brussels, Belgium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States
  • Belgium
  • France
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00401401 on ClinicalTrials.gov